Imaheet 400 — Imatinib 400 mg, 30 pcs, Heet Healthcare

Imaheet 400 — imatinib 400 mg, 30 tablets, Heet Healthcare

Product code: 523

7493₴ 8240₴ -9%

Analogues

1
Active ingredient
Dosage form Tablets
Tablets per pack 30

Imaheet 400 is a targeted anticancer medicine from the Indian company Heet Healthcare, belonging to the protein tyrosine kinase inhibitors. Each tablet contains 400 mg of imatinib. It is a generic imatinib made to the Indian Pharmacopoeia standard (the box reads "Imatinib Tablets IP"): the same active substance and strength as the original medicine Glivec.

Imatinib selectively blocks the Bcr-Abl tyrosine kinase produced by a chromosomal abnormality, the Philadelphia chromosome. It suppresses the growth of Bcr-Abl-positive leukaemia cells and causes their death. Imatinib also inhibits the receptor tyrosine kinases c-Kit (CD117) and PDGFR, so it is used for gastrointestinal stromal tumours (GIST), dermatofibrosarcoma protuberans and several rare blood disorders.

Pack: 30 tablets of 400 mg in a carton. Manufacturer: Heet Healthcare Pvt. Ltd., plant in Barotiwala (Solan district, Himachal Pradesh, India). The medicine is taken by mouth long-term, strictly as prescribed by a haematologist or oncologist.

Key features of Imaheet 400:

  • ✅ Imatinib 400 mg: the same active substance as the original Glivec, the standard of care for chronic myeloid leukaemia and GIST.
  • ✅ Targeted action: selective inhibition of the Bcr-Abl, c-Kit and PDGFR tyrosine kinases.
  • ✅ Convenient strength: one 400 mg tablet is the standard daily dose in chronic-phase CML and GIST.
  • ✅ One-month course: 30 tablets per pack, enough for 30 days at 400 mg a day.
  • ✅ Indian Pharmacopoeia: made to the IP standard at a licensed manufacturing plant.

Imaheet 400 comes as tablets for oral use.

Each tablet contains:

  • • Active substance: imatinib mesylate equivalent to 400 mg of imatinib.
  • • Excipients: listed in the manufacturer's package leaflet.

Pack: 30 tablets in a carton.

Pharmacodynamics:
Imatinib is a protein tyrosine kinase inhibitor. It inhibits the Bcr-Abl tyrosine kinase at the cellular level, selectively suppresses proliferation and induces apoptosis of Bcr-Abl-expressing cells, including leukemic cells in Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGFR) and stem cell factor (c-Kit, CD117), blocking growth signals in gastrointestinal stromal tumor and dermatofibrosarcoma cells.

Pharmacokinetics:

  • • Absorption: mean absolute bioavailability is about 98%. Peak plasma concentrations are reached 2–4 hours after dosing. A high-fat meal has only a minor effect on absorption.
  • • Distribution: about 95% of imatinib is bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
  • • Metabolism: in the liver, mainly by CYP3A4. The main circulating metabolite, the N-demethylated piperazine derivative, has activity similar to the parent drug.
  • • Elimination: the half-life is about 18 hours for imatinib and about 40 hours for the active metabolite. About 81% of the dose is eliminated within 7 days: 68% in feces and 13% in urine.

Imaheet 400 is used in adults and children for:

  • • Chronic myeloid leukemia (CML): newly diagnosed Philadelphia chromosome-positive (Bcr-Abl) CML, and chronic phase after failure of interferon-alpha, accelerated phase or blast crisis.
  • • Ph-positive acute lymphoblastic leukemia (Ph+ ALL): newly diagnosed — combined with chemotherapy; relapsed or refractory — as monotherapy (adults).

In adults only:

  • • Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGF receptor gene rearrangements.
  • • Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.
  • • Gastrointestinal stromal tumors (GIST): Kit (CD117)-positive unresectable and/or metastatic GIST, and adjuvant treatment after resection in patients at significant risk of relapse.
  • • Dermatofibrosarcoma protuberans (DFSP): unresectable, recurrent or metastatic disease not eligible for surgery.

Treatment should be prescribed and dosed only by a physician experienced in treating hematologic malignancies. The dose depends on the diagnosis, disease phase and tolerability.

Usual starting doses in adults:

  • • CML: 400 mg or 600 mg once daily, depending on the disease phase.
  • • GIST: 400 mg once daily.
  • • Ph+ ALL: 600 mg once daily.
  • • MDS/MPD: 400 mg once daily.
  • • HES/CEL: 100 mg daily, may be increased to 400 mg if needed.
  • • DFSP: 800 mg daily — 400 mg in the morning and 400 mg in the evening.

A daily dose of 800 mg is split into two doses: 400 mg in the morning and 400 mg in the evening. A 600 mg dose can be taken as one 400 mg tablet plus two 100 mg tablets.

How to take:

  • • Take with a meal and a large glass of water to protect the stomach lining.
  • • If the tablet is hard to swallow, it can be dispersed in about 200 ml of water or apple juice, stirred with a spoon until fully dissolved and drunk immediately.
  • • Patients with liver or kidney impairment usually receive the minimum dose of 400 mg daily.
  • • Do not stop treatment or change the dose on your own: the duration of therapy is decided by your doctor.

Imaheet 400 must not be used:

  • • In case of hypersensitivity to imatinib or to any of the excipients.

Use with caution (under medical supervision):

  • • in liver, kidney or heart disease, including a history of these conditions;
  • • in patients taking levothyroxine after thyroidectomy;
  • • in patients who have had hepatitis B or may have a current infection: imatinib can cause hepatitis B reactivation;
  • • during pregnancy and breastfeeding (see the pregnancy section);
  • • in children: growth may slow down, so the doctor monitors the child's growth regularly.

During treatment, blood counts, liver and kidney function and body weight (because of possible fluid retention) are monitored regularly.

Tell your doctor about all medicines you take, including over-the-counter and herbal products.

  • • CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin, some antivirals, grapefruit juice) increase imatinib levels and the risk of side effects.
  • • CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, dexamethasone, St John's wort) reduce imatinib levels and may lower its efficacy.
  • • Drugs metabolized by CYP3A4 (simvastatin, ciclosporin, pimozide, some calcium channel blockers and others): imatinib may increase their levels.
  • • Warfarin and other anticoagulants: imatinib affects their action; low-molecular-weight heparins are usually preferred when anticoagulation is needed.
  • • Paracetamol: long-term combined use increases the strain on the liver.
  • • Levothyroxine: the dose may need adjustment after thyroidectomy.

Pregnancy:
Imatinib should not be used during pregnancy unless the doctor considers it clearly necessary: animal studies have shown harm to the fetus. Women of childbearing potential must use effective contraception during treatment.

Breastfeeding:
Imatinib and its active metabolite pass into breast milk. Breastfeeding must be stopped during treatment and for at least 15 days after the last dose.

Fertility:
Patients concerned about their fertility should discuss it with their doctor before starting treatment.

Driving: dizziness, drowsiness and blurred vision may occur; if so, do not drive or operate machinery.

Most side effects of imatinib are mild to moderate. The most common are:

  • • Fluid retention and edema (very common): swelling around the eyes, ankles and legs, weight gain. Rapid weight gain should be reported to the doctor.
  • • Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, indigestion.
  • • Muscles and bones: muscle spasms and cramps, muscle, joint and bone pain.
  • • Blood: decreased neutrophils, platelets and hemoglobin — blood counts are therefore checked regularly.
  • • Skin: rash, itching, dry skin, changes in skin color.
  • • General: weakness and fatigue, headache, dizziness.

Contact your doctor immediately in case of rapid weight gain, shortness of breath, chest pain, signs of bleeding, severe abdominal pain, blood in stool or vomit, yellowing of the skin, severe skin reactions or fever.

Symptoms:
Overdose intensifies the side effects: nausea, vomiting, diarrhea, rash, edema, muscle cramps, marked decrease in blood counts and raised liver enzymes.

What to do:
If you have taken more tablets than prescribed, contact a doctor immediately and take the pack with you. There is no specific antidote; treatment is symptomatic under medical supervision.

Missed dose: if you forget a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed one. Do not take a double dose.

Storage of Imaheet 400:

  • 🌡️ Temperature: store at room temperature in a dry place, protected from light.
  • 💧 Moisture: keep in the original pack.
  • 👶 Safety: keep out of the reach of children.
  • ⏳ Shelf life: shown on the box ("Expiry Date"). Do not use after the expiry date.
  • 📋 Supply: prescription only.

To check that Imaheet 400 by Heet Healthcare is genuine, look for the following:

  • ✅ Box: white carton with the Heet Health Care logo, the text Imatinib Tablets IP 400 mg and IMAHEET 400 Tablets, an Rx mark and a blue band at the bottom reading 30 Tablets.
  • ✅ Side panel: manufacturing licence number Mfg. Lic. No. L/22/2938/MNB, batch number, manufacturing and expiry dates, the maximum retail price in rupees (M.R.P.) per 30 tablets and a barcode.
  • ✅ Manufacturer: Heet Healthcare Pvt. Ltd., Vill. Kotla, Barotiwala-174103, Distt. Solan, Himachal Pradesh (India).
  • ✅ Expiry: the expiry date on the box must not have passed.
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 21.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00